GSK makes CRISPR play, funding Doudna lab in CaliforniaGlaxoSmithKline has forged an alliance with two leading CRISPR researchers that will see the creation of a new Share XGSK makes CRISPR play, funding Doudna lab in Californiahttps://pharmaphorum.com/news/gsk-makes-crispr-play-funding-doudna-lab-in-california/
Novartis builds case for asthma drugs to challenge GSKNovartis has positive data for a two-drug asthma regimen that forms the backbone of its efforts to take Share XNovartis builds case for asthma drugs to challenge GSKhttps://pharmaphorum.com/news/novartis-asthma-drugs-challenge-gsk/
Trial could unlock asthma use for GSK’s TrelegyGlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple Share XTrial could unlock asthma use for GSK’s Trelegyhttps://pharmaphorum.com/news/trial-could-unlock-asthma-use-for-gsks-trelegy/
Shingles vaccine boosts GSK as generic Advair bitesGSK’s first quarter sales beat estimates, helped along by shingles vaccine Shingrix and partly offsetting the effect of Share XShingles vaccine boosts GSK as generic Advair biteshttps://pharmaphorum.com/news/shingles-vaccine-boosts-gsk-as-generic-advair-bites/
FDA approves first treatment for children with lupusThe US FDA has approved GSK’s Benlysta (belimumab) intravenous infusion for the treatment of children with lupus. While Share XFDA approves first treatment for children with lupushttps://pharmaphorum.com/news/fda-approves-first-treatment-children-lupus/
Fulcrum repurposes failed GSK drug for rare diseaseGSK’s failed cardiovascular drug losmapimod looks like it might get a new lease of life after being picked Share XFulcrum repurposes failed GSK drug for rare diseasehttps://pharmaphorum.com/news/fulcrum-repurposes-failed-gsk-drug-for-rare-disease/
Rethinking drug discoveryGeorge Underwood speaks to R&D veteran Dr Paul-Peter Tak about how the drug discovery model needs to change. Share XRethinking drug discoveryhttps://pharmaphorum.com/r-d/views-analysis-r-d/rethinking-drug-discovery/
Pharma’s apprentice army is sculpting the futureA skills gap has been threatening to knock the shine off the UK biotechnology sector’s sparkling reputation for Share XPharma’s apprentice army is sculpting the futurehttps://pharmaphorum.com/r-d/views-analysis-r-d/pharmas-apprentice-army-is-sculpting-the-future/
Q4 results roundup 2019With the full year results season drawing to a close, Richard Staines asks who the winners were and Share XQ4 results roundup 2019https://pharmaphorum.com/sales-marketing/q4-results-roundup-2019/
